This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Unspecified Adult Solid Tumor, Protocol Specific
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

RATIONALE: NG-nitro-L-arginine may stop the growth of tumor cells by disrupting blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of NG-nitro-L-arginine in treating patients with advanced solid tumors.

Provided treatments

  • Drug: NG-nitro-L-arginine
  • Other: laboratory biomarker analysis
  • Other: pharmacological study
  • Procedure: computed tomography
  • Procedure: dynamic contrast-enhanced magnetic resonance imaging

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01324115. The sponsor of the trial is Cancer Research UK and it is looking for 6 volunteers for the current phase.
Official trial title:
A Phase I Trial of NG-Nitro-L-Arginine (L-NNA), a Nitric Oxide Synthase Inhibitor, Given as a Single Intravenous Infusion Over 10 Minutes in Patients With Advanced Solid Tumors